



Applicant and holder: Relaxera Pharmazeutische Gesellschaft mbH & Co. KG

Ref.	Country	Status	Title/Subject	Application date	Appl.No.	Patent
RLX00182AU	AU	Granted	RLX for treating heart failure with preserved ejection fraction	26.05.2015	2015261786	2015261786
RLX00182CA	CA	Filed	RLX for treating heart failure with preserved ejection fraction	26.05.2015	2950037	under examination
RLX00182DEEP	DE	Granted	RLX for treating heart failure with preserved ejection fraction	26.05.2015	15744487.8	3145534
RLX00182FREP	FR	Granted	RLX for treating heart failure with preserved ejection fraction	26.05.2015	15744487.8	3145534
RLX00182GBEP	GB	Granted	RLX for treating heart failure with preserved ejection fraction	26.05.2015	15744487.8	3145534
RLX00182GREP	GR	Granted	RLX for treating heart failure with preserved ejection fraction	26.05.2015	15744487.8	3145534
RLX00182ITEP	IT	Granted	RLX for treating heart failure with preserved ejection fraction	26.05.2015	15744487.8	3145534
RLX00182JP	JP	Granted	RLX for treating heart failure with preserved ejection fraction	26.05.2015	20160569961	6580599
RLX00182JP02	JP	Granted	RLX for increasing cardiac inflow (atrial fibrillation)	28.08.2019	2019155391	6832401
RLX00182US	US	Granted	RLX for treating heart failure with preserved ejection fraction	26.05.2015	15/313,517	10,226,512
RLX00182US02	US	Granted	RLX for increasing cardiac inflow (treatment of atrial fibrillation)	28.01.2019	16/259,448	10,799,561
RLX00183DEEP	DE	Granted	RLX for treating Impaired Glucose Tolerance	22.02.2013	13709063.5	2817026
RLX00183FREP	FR	Granted	RLX for treating Impaired Glucose Tolerance	22.02.2013	13709063.5	2817026
RLX00183GBEP	GB	Granted	RLX for treating Impaired Glucose Tolerance	22.02.2013	13709063.5	2817026
RLX00183US	US	Granted	RLX for treating Impaired Glucose Tolerance	22.02.2013	14380163	10,842,851
RLX00218AUPC	AU	Granted	Process for preparing human relaxin-2	03.08.2012	2012291972	AU2012291972 B2
RLX00218CHEP	CH	Granted	Process for preparing human relaxin-2	03.08.2012	12741355.7	2739647
RLX00218DEEP	DE	Granted	Process for preparing human relaxin-2	03.08.2012	12741355.7	2739647
RLX00218FREP	FR	Granted	Process for preparing human relaxin-2	03.08.2012	12741355.7	2739647
RLX00218INPC	IN	Granted	Process for preparing human relaxin-2	03.08.2012	375/DELNP/2014	405989
RLX00218JP	JP	Granted	Process for preparing human relaxin-2	03.08.2012	20140523338	6276690
RLX00218USPC	US	Granted	Process for preparing human relaxin-2	03.08.2012	14/234919	9434780
RLX00223AUPC	AU	Filed	MEDICAL COMPOSITION FOR TREATING CARDIAC WASTING AND CACHEXIA	16.11.2020	2020382102	under examination
RLX00223EPPC	EP	Filed	MEDICAL COMPOSITION FOR TREATING CARDIAC WASTING AND CACHEXIA	16.11.2020	20819636.0	under examination
RLX00223USPC	US	Granted	MEDICAL COMPOSITION FOR TREATING CARDIAC WASTING AND CACHEXIA	16.11.2020	17776749	12226455
RLX00223USPC01	US	Filed	MEDICAL COMPOSITION FOR TREATING CARDIAC DECOMPENSATION	16.11.2020	19013221	under examination
RLX00236AUPC	AU	Filed	GCR-Agonist - Immunosuppressive Medicament and Method of Treatment	30.08.2023	2023332056	pending
RLX00236BRPC	BR	Filed	GCR-Agonist - IMMUNOSUPPRESSIVE MEDICAMENT AND METHOD OF TREATMENT	30.08.2023	BR112025003965 2	pending
RLX00236CAPC	CA	Filed	GCR-Agonist - Immunosuppressive Medicament and Method of Treatment	30.08.2023	PCT/EP2023/073842	pending
RLX00236CNPC	CN	Filed	GCR-Agonist - Immunosuppressive Medicament and Method of Treatment	30.08.2023	WO2024047130	awaiting filing confirmation
RLX00236EPPC	EP	Filed	GCR-Agonist - IMMUNOSUPPRESSIVE MEDICAMENT AND METHOD OF TREATMENT	30.08.2023	23765189.8	awaiting examintion request
RLX00236INPC	IN	Filed	GCR-Agonist - IMMUNOSUPPRESSIVE MEDICAMENT AND METHOD OF TREATMENT	30.08.2023	WO2024047130	awaiting filing
RLX00236JPPC	JP	Filed	GCR-Agonist - Immunosuppressive Medicament and Method of Treatment	30.08.2023	2025-512783	awaiting examiantion request
RLX00236USPC	US	Filed	GCR-Agonist - Immunosuppressive Medicament and Method of Treatment	30.08.2023	19107096	awaiting examination
RLX00257PC	WO	Filed	Formulation for a daily or bi-daily relaxin-bolus	22.11.2023	PCT/EP2023/082763	not yet published